Morris will leave Axon after two and a half years to take on the newly created role. She will report to head of product comms Susie Hackett, who oversees a PR and PA team of 11.
Morris said she was ‘looking forward to the comms opportunities offered by Roche's diverse portfolio of medicines'.
Tamiflu has hit the headlines as governments stockpile the drug as a potential defence against bird flu.
Prior to Axon, where her clients included ALK-Abelló and Napp Pharmaceuticals, Morris worked at Avenue HKM. Before that she worked in research and development for Pfizer.